

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/594,127
Confirmation Number	8975
Filing Date	September 25, 2006
First Named Inventor	Akio SUGIHARA
Art Unit	1625
Examiner Name	Niloofar RAHMANI
Attorney Docket Number	Q97391

U.S. PATENTS

Examiner Initials*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initials*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T ⁵
	1.	Philippine Office Action issued June 23, 2010 in corresponding Philippine Application No. 1-2006-501883	
	2.	Korean Office Action issued June 16, 2010 in corresponding Korean Application No. 10-2006-7019783	Y
	3.	Third Party Observation issued April 13, 2010 in corresponding European Application No. 05721391.0	
	4.	L. YU, "Amorphous pharmaceutical solids: preparation, characterization and stabilization," Advanced Drug Delivery Reviews, Vol. 48, pp. 27-42 (2001)	
	5.	B. HANCOCK, "Characteristics and Significance of the Amorphous State in Pharmaceutical Systems," Journal of Pharmaceutical Sciences, Vol. 86, No. 1, pp. 1-12 (1997)	
	6.	SOLIFENACIN SUCCINATE: Crystallization experiments (2010)	
	7.	E. SHALAEV et al., "How Does Residual Water Affect the Solid-State Degradation of Drugs in the Amorphous State," Journal of Pharmaceutical Sciences, Vol. 85, No. 11, pp. 1137-1141 (1996)	

EXAMINER SIGNATURE

Examiner Signature	Date Considered
/Niloofar Rahmani/	07/26/2010

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if English language translation is attached.